LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that preclinical data from studies on obesity and cognitive impairment with PRX-07034, a novel, highly selective 5-HT6 receptor antagonist, are the focus of several poster presentations at the Society for Neuroscience (SFN) 36th annual meeting this week in Atlanta, Georgia. Data from these studies provide support for the ongoing Phase 1 clinical program of PRX-07034. This orally available drug candidate is currently being developed for the treatment for obesity and cognitive impairment.
